> Pfizer ($PFE) locked out some employees at a plant in India on Friday, saying that workers had disrupted production lines and threatened some managers. Story

> Pfizer is asking the Nevada Supreme Court to decide if the state's attorney general acted properly by hiring private law firms and agreeing to pay them a contingency fee to handle a case against the drugmaker. Story

> Idenix Pharmaceuticals ($IDIX), which is being bought by Merck ($MRK) for $3.8 billion, reported that it lost about $65 million in the second quarter but has about $178 million in cash on hand. Release

> GlaxoSmithKline ($GSK) said that the Independent Data Monitoring Committee's (IDMC) interim analysis of the PROLONG Phase III study found that its Arzerra hit the primary endpoint of improving progression-free survival in patients with relapsed chronic lymphocytic leukemia (CLL) who responded to treatment at relapse. Release

> European regulators have agreed to undertake an accelerated assessment of Eisai's lenvatinib as a treatment for progressive radioiodine-refractory, differentiated thyroid cancer. Story

> Alexion Pharmaceuticals ($ALXN) announced that the European Commission has granted orphan drug designation (ODD) to Soliris (eculizumab) for the treatment of patients with Myasthenia Gravis (MG). Release